Welcome to 4SC

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development and in early-stage research. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical and biotechnology companies.

4SC AG is listed on the Frankfurt Stock Exchange (Prime Standard: VSC/ISIN DE0005753818), Germany.

18 Aug 2014
4SC AG: Dr Thomas Werner and Klaus Kühn announce resignation from Supervisory Board Planegg-Martinsried, 18 August 2014 - 4SC AG (Frankfurt, Prime Standard: VSC) announces...
4SC-202: positive Phase I data ASCO 2014

Epigenetic compound 4SC-202 shows clean safety and promising signs of efficacy in haematological tumours press release, ASCO 2014 poster

Resminostat: HCC Phase II in preparation

Resminostat: Biomarker ZFP64 high patients show doubling of OS in Phase IIa in HCC... more
Randomised Phase II Study in first line HCC in preparation... more

Learn more about 4SC

Sign up to receive press releases and financial reports... more